QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.091454v1 316/1/456    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mattingly, R. R. Articles by Reiners, J. J. Search for Related Content PubMed PubMed Citation Articles by Mattingly, R. R. Articles by Reiners, J. J., Jr.

CELLULAR AND MOLECULAR

The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines

Wayne State University School of Medicine, Departments of Pharmacology (R.R.M., J.T.D., J.J.R.) and Neurology (B.B., J.A.B.), and Center for Molecular Medicine and Genetics (J.A.B., M.A.T.), Detroit, Michigan; Barbara Ann Karmanos Cancer Institute, Programs in Molecular Biology and Human Genetics (R.R.M., J.M.K., J.E.N., M.A.T.) and in Proteases (J.J.R.), Detroit, Michigan; and Wayne State University, Institute of Environmental Health Sciences (P.M., J.J.R.) and Environmental Health Sciences Center for Molecular & Cellular Toxicology with Human Applications (R.R.M., J.A.B., M.A.T., J.J.R.), Detroit, Michigan

Type 1 neurofibromatosis (NF1) is a common autosomal dominant disorder that results in neuroectodermal tumors. The NF1 tumor-suppressor gene encodes neurofibromin, which includes a GTPase-activating domain for Ras inactivation. Affinity purification showed N-Ras to be the predominant activated isoform of Ras in two independent neurofibrosarcoma cell lines from NF1 patients (lines ST88-14 and NF90-8). These NF1 cells also demonstrated increased constitutive activity of the extracellular signal-regulated kinases 1 and 2 (ERK1,2) mitogen-activated protein (MAP) kinases compared with a sporadic malignant schwannoma cell line that maintains neurofibromin expression (STS-26T). Thus, MAP kinase kinase (MEK) inhibitors may be a rational approach to NF1 therapy. The MEK inhibitors PD98059 [2'-amino-3'-methoxyflavone], PD184352 (also called CI-1040) [2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide], and U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] all produced concentration-dependent suppression of the proliferation of the three cell lines. Individual MEK inhibitors had similar effects in all three cell lines. However, only the antiproliferative effects of PD184352 correlated closely with the elimination of ERK1,2 MAP kinase activities. PD98059 was primarily cytostatic, whereas U0126 and PD184352 were cytotoxic. Only PD184352 induced apoptosis in all three lines, as indicated by morphology, activation of DEVDase, procaspase-3 cleavage, and the appearance of populations having sub-G₀/G₁ DNA contents. The differential effects of the MEK inhibitors on cell survival were not dependent on p53 status or effects on the ERK5 pathway. PD184352 was also proapoptotic to primary rat Schwann cells. Hence, although PD184352 effectively killed neurofibrosarcoma cells, its effects on normal Schwann cells may limit its usefulness in the clinic.

Address correspondence to: Dr. Raymond R. Mattingly, Department of Pharmacology, Wayne State University, 540 East Canfield Ave., Detroit, MI 48201. E-mail: r.mattingly{at}wayne.edu

This article has been cited by other articles:

				J. W. Wojtkowiak, F. Fouad, D. T. LaLonde, M. D. Kleinman, R. A. Gibbs, J. J. Reiners Jr., R. F. Borch, and R. R. Mattingly Induction of Apoptosis in Neurofibromatosis Type 1 Malignant Peripheral Nerve Sheath Tumor Cell Lines by a Combination of Novel Farnesyl Transferase Inhibitors and Lovastatin J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 1 - 11. [Abstract] [Full Text] [PDF]

				G. Johansson, Y. Y. Mahller, M. H. Collins, M.-O. Kim, T. Nobukuni, J. Perentesis, T. P. Cripe, H. A. Lane, S. C. Kozma, G. Thomas, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors Mol. Cancer Ther., May 1, 2008; 7(5): 1237 - 1245. [Abstract] [Full Text] [PDF]

				B. Barkan, S. Starinsky, E. Friedman, R. Stein, and Y. Kloog The Ras Inhibitor Farnesylthiosalicylic Acid as a Potential Therapy for Neurofibromatosis Type 1. Clin. Cancer Res., September 15, 2006; 12(18): 5533 - 5542. [Abstract] [Full Text] [PDF]

				H. Yang and R. R. Mattingly The Ras-GRF1 Exchange Factor Coordinates Activation of H-Ras and Rac1 to Control Neuronal Morphology Mol. Biol. Cell, May 1, 2006; 17(5): 2177 - 2189. [Abstract] [Full Text] [PDF]